SBCH: 22% topline growth in FY01 - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SBCH: 22% topline growth in FY01

Feb 2, 2001

Malted beverages major, Smithkline Beecham Consumer Healthcare Limited (SBCH), has posted a net profit of Rs 317 m in its fourth quarter ended December 31, 2000. This is only 5% up as compared to a net profit of Rs 301 m in the quarter ended December 31, 1999.

(Rs m) FY00 FY01 Change
Sales Turnover 7,057 8,583 21.6%
Other Income 239 289 20.9%
Total Income 7,296 8,873 21.6%
Profit after Tax/(Loss) 976 1,120 14.8%
Net profit margin (%) 13.8% 13.1%  
No. of Shares (eoy) (m) 45.4 45.4  
Diluted Earnings per share* 21.5 24.7  
*(annualised)      
Current P/e ratio   15.8  

However, the company's total income was higher by 31% to Rs 2.5 bn in 4QFY01. The company's annual performance was however, much better. In FY01, SBCH showed a 15% growth in bottomline and a 22% growth in topline.

SBCH is one of the few FMCG companies to show double digit growth in turnover on an annualised basis. The company's performance would have been much better but for its relatively poor 4QFY01 performance.

The poor performance in 4QFY01 also signals that the slowdown in consumption has started nagging SBCH. At the current levels, the SBCH stock quotes at a P/e multiple of 15.8 times its FY01 earnings. However, the bourses will now keenly watch the performance of SBCH in the coming months, so as to determine whether the poor performance in 4QFY01 was a freak incident, or such performances are likely to recur.


Equitymaster requests your view! Post a comment on "SBCH: 22% topline growth in FY01". Click here!

  

More Views on News

GSK CONSUMER Announces Quarterly Results (3QFY20); Net Profit Up 25.1% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, GSK CONSUMER has posted a net profit of Rs 3 bn (up 25.1% YoY). Sales on the other hand came in at Rs 12 bn (up 3.8% YoY). Read on for a complete analysis of GSK CONSUMER's quarterly results.

GSK CONSUMER Announces Quarterly Results (2QFY20); Net Profit Up 25.3% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, GSK CONSUMER has posted a net profit of Rs 3 bn (up 25.3% YoY). Sales on the other hand came in at Rs 13 bn (up 5.7% YoY). Read on for a complete analysis of GSK CONSUMER's quarterly results.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GSK CONSUMER SHARE PRICE


Apr 15, 2020 (Close)

TRACK GSK CONSUMER

  • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK CONSUMER - SANWARIA CONSUMER COMPARISON

COMPARE GSK CONSUMER WITH

MARKET STATS